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Abstract
Brainstem and midbrain areas engage descending facilitatory and inhibitory neurones to potentiate or
suppress the passage of sensory inputs from spinal loci to the brain. The balance between descending
controls, both excitatory and inhibitory, can be altered in various pain states and can critically
determine the efficacy of certain analgesic drugs. There is good evidence for a prominent a2
adrenoceptor-mediated inhibitory system and for 5-HT3 receptor-mediated excitatory control of
spinal cord activity that originates in supraspinal areas. Given the multiple roles of these transmitters
in pain and functions such as sleep, depression, and anxiety, the link between spinal and supraspinal
processing of noxious inputs (via the monoamine transmitters) could be pivotal for linking the
sensory and affective components of pain and their common co-morbidities, and also may potentially
explain differences in pain scores and treatment outcomes in the patient population.
Introduction and context
Descending controls – pathways originating in midbrain
and brainstem regions that project onto the spinal cord –
have long been recognised as key links in the multiple
neuronal networks that interact to produce the overall
pain experience. The potential for higher cognitive
function through cortical controls that project to the
cells of origin of descending controls to influence spinal
function allows for ‘top-down’ processing of pain. The
major transmitter systems implicated in the descending
controls are the monoamines, noradrenaline (NA) and
5-hydroxytryptamine (5-HT), and so the comorbidities
of sleep problems, anxiety, and depression result from
the dual roles of NA and 5-HT in these functions and also
in pain. A number of analgesic drugs interact with
descending controls, including opioids, which have
direct supraspinal interactions with these systems,
pregabalin and gabapentin, whose actions are regulated
by descending pathways, and also the tricyclic antide-
pressants (TCAs) and serotonin and noradrenaline
reuptake inhibitors (SNRIs), which alter synaptic levels
of NA and 5-HT. Tramadol and the newer tapentadol
have mixed mu-opioid receptor and reuptake inhibition
actions, the former with dual NA/5-HT actions and the
latter with NA only. TCAs and SNRIs have greater efficacy
than selective serotonin reuptake inhibitors (SSRIs) in
neuropathic pain, and tapentadol is more powerful than
tramadol. Thus, the potential pronociceptive effects of
increasing levels of 5-HT may counter the analgesic
effects of various molecules. Preclinical data can explain
this on the basis that descending NA actions clearly
mediate inhibitions through spinal a2 adrenoceptor,
whereas 5-HT, via 5-HT2 and 5-HT3 receptors, is a key
transmitter in descending facilitations.
Research has moved on significantly from the early idea
that pain is the product of nociceptive signals linearly
impacting on an alert and responsive brain. Our current
understanding is of a plastic, integrative, and highly
individualised nociceptive system that is subject to many
internal and external influences. Because considerable
processing of nociceptive signals occurs in the spinal
cord, it was reasonably assumed that plasticity (which
enables sensitisation) was an intrinsic function of the
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showed that electrically stimulating an area of the
midbrain, the periaqueductal grey (PAG), resulted in
no overt behavioural signs of distress to an otherwise
painful procedure [1], it became apparent that the brain
could influence pain. It was further shown that stimula-
tion-produced analgesia could be triggered downstream
of the PAG in the rostral ventromedial medulla (RVM)
[2], an area of the brainstem that integrates information
that passes from limbic areas of the brain to the spinal
cord. The PAG and the RVM are therefore key compo-
nents of the descending modulatory repertoire, a system
of neuronal pathways that enables the brain (and thus
cognitive and emotional states) to control pain proces-
sing at the first relays within the spinal cord.
Descending systems depend on feedback circuitry that
relays between the spinal cord and supraspinal areas [3].
Hence, nociceptive signals that arrive in the dorsal horn
from the periphery synapse with spinal neurones that
project to thalamic and parabrachial areas that respec-
tively attach sensory-discriminative (that is, the quality,
intensity, and location of the stimulus) and emotional/
contextual meaning to the signal. Partly on the basis of
this received information, limbic, cognitive, and somatic
areas in turn send out signals that converge and feed into
descending pathways to either increase or decrease the
influence of further incoming input into the dorsal horn,
causing the feedback cycle to continue. The neural bases
for this bidirectional modulation from the brainstem are
the ‘On’ and ‘Off’ cells; On cells burst-fire in response to
peripheral noxious stimuli,enhance nociception, and are
implicated in the hypersensitivities associated with a
range of pain states, whereas Off cells undergo a pause in
firing in response to peripheral noxious stimuli and are
involved in inhibiting spinal neuronal activity [4].
Incidentally, and importantly, the responses of these
RVM neurones to noxious stimuli are inversely predi-
ctive of their responses to systemic or brainstem opioid
administration, and hence On cells are inhibited by
morphine whereas Off cells are disinhibited [5].
Recent advances
The original notion of descending controls was that they
were predominantly inhibitory in nature, but this has
been broadened and refined so that we now know that
the brainstem’s output (likely via the On cells) can be
predominantly facilitatory (particularly with respect to
high-intensity stimuli) and that this may be the main
physiological function [6]. This ‘gain control’ ensures the
detection of (and appropriate response to) noxious
inputs. The balance between supraspinal inhibition and
facilitation can, however, be altered, either transiently or
durably (for example, in some cases of chronic pain).
With respect to the former, descending inhibitory path-
ways can be activated and endogenous analgesia
recruited so that nociception and protective responses
to noxious stimuli are temporarily suppressed in
situations of threat and danger. In terms of longer-
lasting alterations in descending output, the RVM may
serve a protective, or ‘masking’, role during some pain
states by increasing its inhibitory output (for example,
during inflammatory pain and potentially during the
early stages of cancer). The descending system may,
however, become maladaptive so that pain outlasts its
biological usefulness; after neuropathy, aberrant neuro-
nal activity can increase the descending facilitatory drive
to maintain the pain state, yet after the injury is healed,
descending facilitatory neurones may fail to disengage,
which means that they continue to enhance the
transmission of sensory input. These mechanisms not
only contribute to the neuropathic pain state but also are
permissive for the efficacy of gabapentinoid drugs [7,8].
Because one mechanism by which descending neurones
achieve this is through enhancing the evoked transmitter
release from peripheral nerves [9], the feed-forward
compensatory circuit between the periphery, spinal cord,
and supraspinal structures becomes self-sustaining and
therefore could give rise to chronic pain. Indeed, these
supraspinal influences appear to be prominent in the
maintenance of persistent pains but not in their
induction, suggesting that at first the pain states are
driven by peripheral processes but that with time the
pain drive moves higher up the neuraxis. In addition to
providing insight into neuropathic pain, abnormal
activity in this loop may shed some mechanistic light
on diffuse pain states that lack simple peripheral causal
explanations, such as fibromyalgia [10].
The specialised role of midbrain and brainstem areas in
pain processing has been demonstrated not only in
animal studies but in human subjects too; human
imaging studies have shown that supraspinal activations
during painful stimulation significantly localised in
regions consistent with the nucleus cuneiformis and
PAG [11], areas that collectively form the major source of
input to the RVM. Furthermore, when the pattern of
brain activity evoked by cold pain versus cold allodynia
is compared in human volunteers, areas within the
dorsolateral pons (that are consistent with the parabra-
chial area) are recruited in the processing of the latter,
which verifies the role of the brainstem during central
sensitisation [12]. This is consistent with analyses of
brainstem activity during dynamic mechanical allodynia,
which highlighted neuronal changes and increased
activity in the ipsilateral dorsal medulla/upper cervical
cord in an area consistent with the location of the RVM
[13]. Thus, together with diffusion tractography
Page 2 of 4
(page number not for citation purposes)
F1000 Medicine Reports 2009, 1:83 http://F1000.com/Reports/Medicine/content/1/83techniques that confirm anatomical pathways mediating
top-down control of nociceptive processing in humans
[14], these imaging studies provide a clear picture of the
brainstem’s representation of pain and central sensiti-
sation in humans and reinforce the importance of
descending modulatory systems, first mapped out in
animals, to human correlates of the pain experience.
Implications for clinical practice
Pain doctors should therefore be aware that descending
controls can have a major impact on the patient’sp a i n
experience where top-down modulation can be influ-
enced by mood, fear, or sleep, for example. Plausibly, the
balance between facilitatory and inhibitory controls could
be influenced by coping or catastrophising. Preclinical
data show descending facilitations dominating inhibi-
tions in disparate models that include peripheral neuro-
pathy, spinal cord injury, cancer-induced bone pain, and
opioid-induced hyperalgesia. Currently, the role of
descending facilitations in clinical pains can be surmised
by human imaging studies (as discussed above) in which
activation of midbrain and brainstem structures in
situations in which the pain rating is high is indicative
of their facilitatory roles. On the other hand, the
functional status of inhibitions can be evinced in some
clinical situations, such as in their failure in patients with
fibromyalgia [15]. Even here, the reduction in inhibition
could be secondary to enhanced facilitations [10]. Some
diffuse pain conditionsmaytherefore beunderscoredbya
malfunction of central neuronal systems that control
mood, sleep, and pain such that a generalised pain state
could be generated in the absence of overt peripheral
pathology. In pains of peripheral origins, descending
facilitations act alongside spinal mechanisms of hyper-
sensitivity to further shift the pain score upwards.
Clinicians should also be aware that descending controls
do not just modulate the pain state but are permissive for
the actions of several important drug classes. The
analgesic effects of TCAs, SNRIs, and the new mu-opioid
receptor agonist and noradrenaline reuptake inhibitor
tapentadol, for example, rely on altering activity at
monoamine synapses and therefore are dependent on
activity in the descending circuits (the weaker analgesic
efficacy of SSRIs is explicable in terms of the established
noradrenergic inhibitory tone that contrasts with certain
pronociceptive effects of 5-HT). Furthermore, because
gabapentin and pregabalin have efficacies that are
dependent on activity within descending circuits [7,8],
individual variations in pain comorbidities may explain
why there are variable responses to treatments such as
gabapentin and pregabalin in seemingly uniform pain
groups [16]. Indeed, despite consistent efficacy in most
animal models of neuropathic pain in which these
co-morbid factors and societal influences may have less
of an impact than in chronic pain patients, there is an ill-
defined link between the presence of nervous system
lesions or abnormal sensory phenomena and the respon-
siveness to gabapentinoid drugs in the clinic [17]. Clinical
investigations relating the analgesic efficacy of TCAs,
SNRIs, and gabapentinoids with affective measures may
therefore be a step toward predicting treatment respon-
siveness in patients.
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